A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to estimate progression free survival in patients with recurrent
or metastatic head and neck cancer that have not received chemotherapy in this setting.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Cetuximab Cisplatin Folic Acid Hydroxocobalamin Pemetrexed Vitamin B 12 Vitamin B Complex Vitamins